News & Updates
Showing Oncology articles
Showing

Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.

Healthy living puts colorectal cancer at bay
As cliché as it sounds, adopting a healthy lifestyle helps prevent the development of colorectal cancer (CRC). A recent study has shown that adhering to well-balanced diet, maintaining a normal weight, staying physically active, and avoiding tobacco and alcohol all contribute to a reduction in CRC risk.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC
Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer
Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).




